💊Biotech Boom: Relay & Summit Surge on Positive Cancer Trials, Natera Preps ESMO Data, and Moderna Expands mRNA Reach in Canada | Biotech Sector Insights
Significant contributors to this performance include Moderna (MRNA), which reported a notable increase, and Amgen (AMGN), which announced positive data regarding its IMDELLTRA treatment for extensive-stage small cell lung cancer, demonstrating promising disease control rates.
Welcome to the MarketReader Minute.
Below are AI-generated insights on moves in the health care/biotechnology sector, powered by MarketReader technology.
Monday, September 9
IBB [+0.7%]
The iShares Biotechnology ETF (IBB) has increased by 1.0% during market hours on Monday. Significant contributors to this performance include Moderna (MRNA), which reported a notable increase, and Amgen (AMGN), which announced positive data regarding its IMDELLTRA treatment for extensive-stage small cell lung cancer, demonstrating promising disease control rates. Regeneron Pharmaceuticals (REGN) also highlighted encouraging data on its LAG-3 inhibitor in advanced melanoma, while Natera Inc. (NTRA) is set to present findings from the CIRCULATE-Japan trial, showcasing a substantial survival advantage linked to its colorectal cancer test. Additionally, the Dow Jones Index has risen by 1.15%, reflecting broader market sentiment that may correlate with the movement in IBB.